Table 2.
Differences in outcomes by CPAP adherence.
| Betaa | P | CPAP-Adherent | CPAP-Nonadherent | |||
|---|---|---|---|---|---|---|
| People With Data (n) | Total Observations (n) | People With Data (n) | Total Observations (n) | |||
| Renal function testsb,c | ||||||
| eGFRd (log) (mL/min/1.73 m2) | –0.03 | .48 | 109 | 438 | 136 | 651 |
| eGFRd ≥ 60 (log) (mL/min/1.73 m2) | –0.03 | .32 | 76 | 220 | 95 | 322 |
| eGFRd ≥ 30 (log) (mL/min/1.73 m2) | –0.05 | .10 | 101 | 374 | 123 | 527 |
| Blood pressureb,e | ||||||
| SBPd (mm Hg) | –1.95 | .001 | 183 | 3,053 | 215 | 3,910 |
| DBPd (mm Hg) | –2.33 | < .0001 | 183 | 3,052 | 215 | 3,906 |
| Lipidsb,f | ||||||
| Cholesterol (mg/dL) | –1.22 | .86 | 65 | 97 | 90 | 149 |
| LDL (mg/dL) | 0.43 | .94 | 62 | 93 | 88 | 141 |
| HDL (mg/dL) | 3.34 | .06 | 64 | 95 | 89 | 148 |
| Triglycerides (log) (mg/dL) | –0.16 | .07 | 64 | 95 | 89 | 147 |
| Glycemic controlb | ||||||
| HbA1c (log) (%) | –0.01 | .73 | 39 | 47 | 59 | 88 |
| Odds Ratio (95% CI) | P | Number of Events | Number of Events | |||
| Incidence of vascular diseaseb,e,f | ||||||
| CVD | 1.13 (0.63–2.02) | .68 | 27 | 34 | ||
| PVD | 1.05 (0.54–2.03) | .89 | 19 | 26 | ||
| CVA | 0.85 (0.41–1.79) | .68 | 14 | 23 | ||
aBeta: CPAP-adherent—CPAP-nonadherent. bAdjusted for BMI, age at time of PSG, sex, number of diabetes medications ever used, any history of insulin use. cAdjusted for any history of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use. dAdjusted for baseline value of outcome. eAdjusted for number of hypertension medications ever used. fAdjusted for any history of lipid medication use. BMI = body mass index, CI = confidence interval, CPAP = continuous positive airway pressure, CVA = cerebrovascular accident, CVD = cardiovascular disease, DBP = diastolic blood pressure, eGFR = estimated glomerular filtration rate, HbA1c = hemoglobin A1c, HDL = high-density lipoprotein, LDL = low-density lipoprotein, PSG = polysomnography, PVD = peripheral vascular disease, SBP = systolic blood pressure.